Royal Bank of Canada
RAPP

Royal Bank of Canada’s Rapport Therapeutics RAPP Stock Holding History

Royal Bank of Canada’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Sell
225
-875
-80% -$24.6K ﹤0.01% 6344
2025
Q4 		$33K Buy
1,100
+8
+0.7% +$221 ﹤0.01% 5784
2025
Q3 		$32K Sell
1,092
-478
-30% -$8.53K ﹤0.01% 6020
2025
Q2 		$18K Buy
1,570
+259
+20% +$2.75K ﹤0.01% 6311
2025
Q1 		$13K Buy
1,311
+319
+32% +$4.14K ﹤0.01% 6081
2024
Q4 		$18K Sell
992
-480
-33% -$10.6K ﹤0.01% 6158
2024
Q3 		$31K Buy
1,472
+1,247
+554% +$26.8K ﹤0.01% 5921
2024
Q2 		$5K Buy
+225
New +$5.21K ﹤0.01% 6558

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Royal Bank of Canada's RAPP Position: Q1 2026 in Review

Royal Bank of Canada reduced its Rapport Therapeutics (RAPP) stake by 80% in Q1 2026, selling an estimated $24.6K and leaving 225 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6344.

Royal Bank of Canada first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $33K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Royal Bank of Canada held 225 shares of Rapport Therapeutics worth $7K as of Q1 2026.
  • Royal Bank of Canada sold 875 Rapport Therapeutics shares in Q1 2026, an estimated $24.6K.
  • Rapport Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6344 holding.
  • Royal Bank of Canada first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Royal Bank of Canada's Rapport Therapeutics position peaked at $33K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.